Liquidia (LQDA) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Liquidia (LQDA) over the past year, gaining 41.2% versus a gain of 11.0%. Over five years, LQDA leads with a +733.8% price change compared with +100.5% for PHVS. Liquidia is the larger company by market cap ($2.51 billion vs $2.17 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | PHVS |
|---|---|---|
| Share price | $28.09 | $30.97 |
| Market cap | $2.51B | $2.17B |
| 1-day change | +5.28% | -2.26% |
| YTD return | -22.64% | +14.16% |
| 1-year return | +11.03% | +41.18% |
| 5-year return | +733.75% | +100.51% |
| P/E ratio (TTM) | 20.21 | — |
| Forward P/E | 11.68 | — |
| EPS (TTM) | $1.39 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $93.61 | $43.25 |
| 52-week low | $21.94 | $20.65 |
| Distance from 52-week high | -69.99% | -28.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.82% | +84.79% |
| Average volume | 2.40M | 731.42K |
| Shares outstanding | 89.51M | 70.20M |
| Employees | 216 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed LQDA by 30.1 percentage points over the past year.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
LQDA vs PHVS FAQ
Which is bigger, Liquidia or Pharvaris N.V.?
Liquidia (LQDA) is larger, with a market capitalization of $2.51B compared with $2.17B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, LQDA or PHVS?
PHVS returned +41.18% over the past 12 months, compared with +11.03% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.